Immune modulator-induced changes in the gastrointestinal tract

Histopathology

Volumn 71, Issue 3, 2017, Pages 494-496

  Bavi, Prashant ^a   Butler, Marcus ^a   Serra, Stefano ^a   Chetty, Runjan ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; COLLAGENOUS COLITIS; COLON BIOPSY; CYTOTOXIC T LYMPHOCYTE; DRUG INDUCED DISEASE; DUODENUM BIOPSY; ESOPHAGUS BIOPSY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTESTINE BIOPSY; INTRAEPITHELIAL LYMPHOCYTOSIS; LETTER; LYMPHOCYTE; LYMPHOCYTOSIS; MELANOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; STOMACH BIOPSY; TUMOR MICROENVIRONMENT; GASTROINTESTINAL TRACT; IMMUNOLOGY;

GASTROINTESTINAL TRACT; HUMANS;

EID: 85019266507     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13224     Document Type: Letter

References (6)

1. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. Pd-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 2017; 70; 558–567.
2. Brower V. Checkpoint blockade immunotherapy for cancer comes of age. J. Natl Cancer Inst. 2015; 107; djv069.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348; 56–61.
4. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an ‘innocent bystander’. Toxins 2014; 6; 914–933.
5. Baroudjian B, Lourenco N, Pages C et al. Anti-pd1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016; 26; 308–311.
6. Taube JM, Klein A, Brahmer JR et al. Association of pd-1, pd-1 ligands, and other features of the tumor immune microenvironment with response to anti-pd-1 therapy. Clin. Cancer Res. 2014; 20; 5064–5074.